Regen BioPharma Inc (RGBP)

[OTCShotCaller]

BIG MOVES BEING MADE + INSTITUTIONAL INVESTORS MOVING IN ON RGBP

https://investingbulletin.com/2021/04/regen-biopharma-inc-rgbp-signals-its-ambition-to-go-otc-pink-current-with-recent-8k-filing/

On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment of pancreatic cancer for a term of 15- years.

The License IP consists of an antigen specific cancer vaccine in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.

Interestingly, the Company has a number of high profile products in its pipeline:

Aplastic Anemia Stem Cell Therapy

HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I/II CLINICAL TRIALS

Breast Cancer – dCellVax – IND #16200

Myelodysplastic Syndrome Gene Silencing – DiffronC

Additionally, The Company (RGBP) has attracted the attention of investment “institutions”, i.e. The Asset Management, LLC has invested over $1.1 million dollars into the company, as seen below in obtained SEC ownership breakdown. LG Capital Funding, LLC, Asset Management now owns a total of 5.3%.

Additionally

On Friday, April 9th, Regen Biopharma, Inc. (RGBP) filed an 8-K outlining its ambitious plan to upload a series of filings that would satisfy the SEC and OTC requirements to bring the company back to reporting status with OTC markets, allowing it to up-list to OTC Pink Current status.

RGBP 8K Filings

Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements).
Upon completion of the aforementioned audits and reviews and preparation of the required reports, the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:

• Form 10-K for the Fiscal Year ended September 30, 2019
• Form 10-Q for the Quarter ended December 31, 2019
• Form 10-Q for the Quarter ended March 31, 2020
• Form 10-Q for the Quarter ended June 30, 2020
• Form 10-K for the Fiscal Year ended September 30, 2020
• Form 10-Q for the Quarter ended December 31, 2020

It's ALL good now!

Be well and prosper..